as of 09-01-2026 12:10pm EST
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables, with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by Europe, the Middle East, and Africa (33%) and Asia-Pacific (15%).
| Founded: | 1986 | Country: | Netherlands |
| Employees: | N/A | City: | N/A |
| Market Cap: | 9.0B | IPO Year: | 1998 |
| Target Price: | $45.76 | AVG Volume (30 days): | 3.1M |
| Analyst Decision: | Buy | Number of Analysts: | 8 |
| Dividend Yield: | Dividend Payout Frequency: | N/A | |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $32.53 - $57.81 | Next Earning Date: | 05-06-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | 8.18% | Revenue Growth (next year): | 5.71% |
| P/E Ratio: | 24.01 | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | -10.49% |
See how QGEN stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "QGEN Qiagen N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.